{"doi":"10.1016/j.cpt.2025.08.005","title":"Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study","abstract":null,"journal":"Cancer Pathogenesis and Therapy","year":2026,"id":637664,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":987276,"name":"Yining Liu","orcid":"0000-0002-6487-7595","position":1,"is_corresponding":false},{"id":1027115,"name":"Lijie Wang","orcid":"0000-0001-8674-3128","position":2,"is_corresponding":false},{"id":1213841,"name":"Jinliang Wang","orcid":"0000-0002-5034-8131","position":3,"is_corresponding":false},{"id":1655843,"name":"Junxun Ma","orcid":null,"position":4,"is_corresponding":false},{"id":1000472,"name":"Guoqing Zhang","orcid":"0000-0003-3155-8915","position":5,"is_corresponding":false},{"id":1655845,"name":"Zhefeng Liu","orcid":null,"position":6,"is_corresponding":false},{"id":1235269,"name":"Yi Hu","orcid":"0000-0002-2800-5650","position":7,"is_corresponding":false},{"id":1655841,"name":"Haitao Tao","orcid":"0009-0001-1295-8692","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study","abstract":"Background Immune checkpoint inhibitors combined with PARP inhibitors and chemotherapy can enhance anti-tumor activity. This phase Ib clinical study was designed to evaluate the safety and efficacy of cisplatin in combination with sintilimab and niraparib in patients with advanced solid tumors. Methods Patients with advanced solid tumors who had progressed after first-line or more lines of standard therapy were enrolled in the study, and received cisplatin and sintilimab on day 1 and niraparib from days 1–21 every 3 weeks for up to 4 cycles, followed by maintenance therapy with sintilimab and niraparib (the same doses and schedules as before), until disease progression, death, or intolerable toxicities. During the dose-escalation phase, patients were divided into three dose groups on the basis of a 3+3 dose-escalation regimen, and a dose-expansion phase was conducted based on the determined maximum tolerated dose (MTD). The primary endpoint was safety, including treatment-related adverse events (TRAEs), dose-limiting toxicity (DLT), and the recommended phase 2 dose (RP2D), and the secondary endpoint was efficacy. In addition, exploratory endpoints were prespecified to analyze potential biomarkers. Results From July 31, 2019, to July 1, 2022, a total of 26 patients were enrolled, and no DLTs were observed in the dose-escalation phase. The recommended RP2Ds of cisplatin, sintilimab, and niraparib were 60 mg/m 2 , 200 mg, and 100 mg every 3 weeks, respectively. All of the patients experienced varying degrees of TRAEs, and a 19.23% (5 patients) incidence of immune-related adverse events (irAEs). With the median follow-up time of 47.9 months (95% CI: 38.8–NA), objective response rate was 26.92% (7 patients, 95% confidence interval [CI], 11.57–47.79), disease control rate was 57.69% (15patients, 95% CI, 36.92–76.65), the median progression-free survival (PFS) was 3.30 months (95% CI, 2.14–4.46) and the median overall survival (OS) was 8.03 months (95% CI, 3.41–12.66), with PFS rates of 26.92% (seven patients) and 11.54% (three patients) at 6 and 12 months, and OS rates of 69.23%, 34.62% and 11.54% at 6, 12 and 24 months, respectively. Patients with programmed cell death ligand 1 (PD-L1) expression ≥1% showed significantly longer PFS (3.93 months, P = 0.032) and OS (14.97 months, P = 0.036) compared to those with PD-L1 expression <1%. Conclusion The combination of cisplatin with sintilimab and niraparib showed a manageable safety profile and modest anti-tumor activity in patients with advanced solid tumors. Further validation in larger, histology-specific patients is needed to confirm clinical benefit. Trial registration: https://www.chictr.org.cn/ ; ID: ChiCTR1900024488","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41394111","pmcid":"PMC12701673","openalex_id":"https://openalex.org/W4413805259","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.24153163,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.cpt.2025.08.005","host_type":"journal"},{"url":"https://doi.org/10.1016/j.cpt.2025.08.005","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2949713225000965?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2949713225000965?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41394111","host_type":"repository"},{"url":"https://doaj.org/article/f36b764de802469aa1bb4052b6d1845b","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12701673/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12701673","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12701673?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["PARP inhibition in cancer therapy","Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research"],"mesh_terms":[],"keywords":["Cisplatin","Oncology","Phase (matter)","Medicine","Internal medicine","Chemotherapy","Chemistry","Neoplasms","Immunotherapy","Niraparib","Sintilimab"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T19:18:44.038810Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}